Ex Vivo Gamma H2ax Radiation Sensitivity Assay In Prostate Cancer: Inter-Patient And Intra-Patient Heterogeneity

Introduction: The aim of the study is to assess inter-patient and intralpatient heterogeneity in tumour cell radiosensitivity using the ex vivo gamma H2AX assay in prostate cancer specimens.Methods: Excised specimens from untreated prostate cancer patients were cultivated 24 h in media, irradiated ex vivo and fixed after 24 h. Residual gamma H2AX foci were counted and the slope of the dose response was calculated. Intra-patient heterogeneity was studied from three to seven different biopsies.Results: In pathology-confirmed tumour samples from 21 patients the slope of residual gamma H2AX foci and radiation dose showed a substantial heterogeneity ranging from 0.82 to 3.17 foci/Gy. No correlation was observed between the slope values and the Gleason score (p = 0.37), prostate specific antigen (p = 0.48) and tumour stage (p = 0.89). ANOVA indicated that only in 1 out of 9 patients, biopsies from different tumour locations yielded statistically significant differences. Variance component analysis indicated higher inter-patient than intra-patient variability. Bootstrap simulation study demonstrated that one biopsy is sufficient to estimate the mean value of residual gamma H2AX per dose level and account for intra-patient heterogeneity.Conclusions: In prostate cancer inter-patient heterogeneity in tumour cell radiation sensitivity is pronounced and higher than intra-patient heterogeneity supporting the further development of the gamma H2AX ex vivo assay as a biomarker for individualized treatment. (C) 2017 Elsevier B.V. All rights reserved.